Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

As reported by NDTV Profit - Latest

Zydus' innovation portfolio is also emerging as a meaningful growth driver in the US. The innovative products contribute around 10% of the company's US revenue and remain highly profitable.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on NDTV Profit - Latest ↗

Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.

COMPANIES India’s space economy may grow 5x to $45 billion by 2030. Who is leading the boom? Stocks-Markets-Economic Times
COMPANIES Bombay Burmah Trading shares surge 14% after SC recalls Rs 4,655 crore lease-rent observation Stocks-Markets-Economic Times
INDIAN US Stock Market: Software stocks brace for more volatility as AI uncertainty grows Markets-Economic Times
INDIAN Skyways Air IPO Day 4: GMP signals 31% listing premium; issue subscribed over 5 times Markets-Economic Times
INDIAN Nvidia Q2 FY2027 earnings: AI boom rolls on, but new questions emerge Markets-Economic Times
COMPANIES Hindustan Copper shares fall 3%, multibagger stock drops 6% in 3 days as OFS concludes. What lies ahead? Stocks-Markets-Economic Times
COMPANIES Vijay Kedia’s portfolio: How the ace investor’s top 5 stock holdings performed in a month Stocks-Markets-Economic Times
COMPANIES These 19 Indian stocks turned into tenbaggers in 5 years: Peter Lynch’s rules to find the next Stocks-Markets-Economic Times

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

More from Market Samachar